Objective
Tuberculosis (TB) remains one of the most devastating infectious diseases worldwide, killing over 4,000 people every day. Prevention of tuberculosis infection by novel vaccines would provide the most cost-effective approach to achieve the goals of the WHO End TB strategy and the Sustainable Development Goals of the United Nations.
While there are few promising TB vaccine candidates available, innovation by new platforms and strategies is needed to ensure that the most effective and affordable vaccines are developed.
TBVACHORIZON will innovate and diversify the global TB vaccine pipeline by pursuing four objectives:
1. Define the composition, spatial organisation and functioning of protective immune responses in the Mycobacterium tuberculosis-infected lung.
2. Evaluate whether mucosal re-vaccination with BCG and other live attenuated vaccines improves protective efficacy against tuberculosis infection in mice, non-human primates and humans.
3. Identify host immune response profiles and biomarkers of natural and vaccine-induced immune protection in the lung.
4. Support next generation TB vaccine development by standardised head-to-head testing of selected vaccine candidates in animals and the establishment of novel delivery systems, adjuvant formulations and GMP platforms for live attenuated vaccines.
TBVACHORIZON will increase our understanding and develop tools pertaining to immune protection in the lung, the major site of tuberculosis infection. This knowledge will be exploited to develop mucosal strategies for translating towards clinical evaluation and possible implementation. The interwoven activities will consolidate Europe’s leading role in TB vaccine research and innovation, with the ultimate goal of accelerated availability of affordable, accessible and more effective TB vaccines.
Fields of science
- natural sciencesbiological scienceszoologymammalogyprimatology
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
8219 PK LELYSTAD
Netherlands
See on map
Participants (11)
2288 GJ Rijswijk Zh
See on map
75794 Paris
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
31062 Toulouse Cedex 9
See on map
00149 Roma
See on map
75724 Paris
See on map
59019 Lille
See on map
2333 ZA Leiden
See on map
2300 Kobenhavn S
See on map
50009 Zaragoza
See on map
89081 Ulm
See on map
36410 PORRINO
See on map
Partners (7)
4051 Basel
See on map
1228 Plan Les Ouates
See on map
LS2 7UE Leeds
See on map
WC1E 7HT London
See on map
E14 4PU London
See on map
LE1 7RH Leicester
See on map
OX1 2JD Oxford
See on map